Meta-analysis · people

Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophy

Checked against the paper Meta-analysisPublished by PepVault

The takeaway

Across placebo-controlled trials in HIV lipodystrophy, tesamorelin on average lowered deep belly and liver fat and added lean mass, with joint, muscle and injection-site complaints as the side effects seen.

Kind
Meta-analysis
Studied in
People
Published
2026
Journal
Obes Res Clin Pract

What they tested

The team asked how tesamorelin, compared with placebo, changes body fat, liver fat, metabolic and hormone markers, and side effects in adults with HIV-associated lipodystrophy.

How the study was done

A systematic review and meta-analysis that pooled a small number of randomized controlled trials comparing tesamorelin with placebo (a dummy treatment) in adults with HIV. Databases were searched through July 2025, and results were combined with a random-effects model.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking tesamorelin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Compared with placebo, tesamorelin was linked to less visceral fat, the deep fat around the organs (mean difference -27.71 cm²), less trunk fat (-1.18 kg), less limb fat (-0.22 kg), a lower hepatic fat percentage (-4.28%), and a smaller waist (-1.61 cm). Lean body mass rose by 1.42 kg. Subcutaneous fat, the fat just under the skin, and BMI did not drop significantly, and CD4 T-cell counts did not change. Side effects included joint pain, muscle pain, tingling (paresthesia), and injection-site redness, and the authors concluded there were no serious side effects or changes in glucose.

What it doesn’t show

It pools only a handful of trials, all in adults with HIV, so it does not show how tesamorelin works in people without HIV. BMI and subcutaneous fat did not change, so the effect was on specific fat stores rather than on BMI.

The paper

Badran et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026.

The compound

More studies on Tesamorelin

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tesamorelin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo